PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
The user has seen improvement in their hair loss after 6.5 months on finasteride, 8 months on Minoxidil and RU58841, and using Nizoral twice a week. Commenters suggest adding microneedling to the treatment regimen for potentially better results.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
A 20-year-old shared progress on hair regrowth after 7.5 months of minoxidil and 2 months of finasteride, reporting no negative side effects and healthier hair. The user also improved their diet, stopped creatine, and experienced positive changes in hair and overall appearance.
A 37-year-old man experienced significant hair regrowth over nine months using a topical solution of 5% Minoxidil and 0.3% Finasteride. He reported no side effects and noted the treatment's effectiveness despite initial dosage confusion.
The conversation is about starting a hair loss treatment using a topical solution containing RU58841, Minoxidil, and Copper Peptides. The user plans to test the product and share updates on its effectiveness.
The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.